Antisense-based cancer therapeutics: are we there yet?

Area of Science:

• Molecular Biology
• Oncology
• Pharmacology

Background:

• There is a persistent need for improved, less toxic cancer therapeutics.
• Antisense oligonucleotides represent a novel molecular therapeutic strategy.
• Several antisense agents are in preclinical and clinical development for cancer.

Purpose of the Study:

• To highlight the potential of antisense oligonucleotides as a cancer therapy.
• To discuss the challenges and recent progress in developing antisense strategies for cancer.
• To explore the role of antisense oligonucleotides in combination cancer treatment.

Main Methods:

• Review of current research on antisense oligonucleotide development for cancer.
• Analysis of advancements in chemical modifications, target selection, and drug delivery.
• Evaluation of clinical trial data for anticancer antisense drugs.

Main Results:

• Antisense oligonucleotides show promise as a nucleic acid-based cancer therapeutic approach.
• Progress in chemical modifications, target selection, and delivery systems is addressing development challenges.
• Antisense oligonucleotides are emerging as a viable option for monotherapy or combination therapy.

Conclusions:

• Antisense oligonucleotides are a promising novel approach for human cancer therapy.
• Continued progress in the field is expected to overcome existing limitations.
• These agents can be used independently or integrated with conventional cancer treatments.